Teclistamab Plus Nirogacestat Elicits Durable Responses in Relapsed/Refractory Myeloma
The combination of teclistamab and nirogacestat produced high and deep responses in patients with relapsed/refractory multiple myeloma.
The combination of teclistamab and nirogacestat produced high and deep responses in patients with relapsed/refractory multiple myeloma.
Maurie Markman, MD, expands on the debate regarding the appropriate primary outcome end point for improved clinical benefit in a trial.
Naval G. Daver, MD, highlights ongoing research efforts in relapsed/refractory AML, including combination regimens and pathways targeted by novel agents.
Jonathan E. Rosenberg, MD, discusses how recent FDA approvals have revolutionized the treatment paradigm for locally advanced or metastatic bladder cancer.
Changchun Deng, MD, PhD, discusses factors to consider when sequencing covalent BTK inhibitors and venetoclax in patients with CLL/SLL.
Kian-Huat Lim, MD, PhD, discusses the role of multidisciplinary collaboration and clinical trials in the treatment of pancreatic cancer.
Karim Chamie, MD, discusses the significance of the FDA approval of N-803 plus BCG in BCG-unresponsive non–muscle invasive bladder cancer.
A multipeptide vaccine combination approach with 12MP plus 6MHP vs 12MP plus tet extended overall survival in patients with stage IIB to IV melanoma.
Eftilagimod alpha plus radiotherapy and pembrolizumab was safe and displayed initial activity in soft tissue sarcoma.
Acalabrutinib combination therapy elicits statistically significant improvement in progression-free survival for treatment-naive mantle cell lymphoma.
Darolutamide uptake in metastatic hormone-sensitive prostate cancer has become routine both in doublet and triplet regimens in community urology practices.